Supplementary Table 1. Total CS Dose Exposure in mg From Maintenance Baseline to Week 58 in the Filgotinib 200 mg Group in Total and by Presence or Absence of CS-Free Remission in Patients Treated with CS at Maintenance Baseline

Induction baseline characteristic	Filgotinib 200 mg		
	Total (n = 92)	CS-free remission[a] (n = 25)	No CS-free remission[b] (n = 67)
Overall			
No.	92	25	67
Mean (95% CI)	213.7 (161.37–266.04)	145.7 (95.09–196.31)	239.1 (170.01–308.15)
Median (Q1–Q3)	150.0 (56.25–270.00)	120.0 (60.00–225.00)	180.0 (52.50–297.50)
Sex			
Female (ref)			
No.	53	19	34
Mean (95% CI)	178.1 (127.45–228.72)	125.1 (75.57–174.70)	207.7 (133.74–281.61)
Median (Q1–Q3)	180.0 (37.50–240.00)	120.0 (26.25–195.00)	187.5 (43.12–268.75)
Male			
No.	39	6	33
Mean (95% CI)	262.1 (158.29–365.93)	210.8 (37.14–384.53)	271.4 (150.17–392.69)
Median (Q1–Q3)	135.0 (60.00–327.50)	172.5 (75.00–315.00)	135.0 (60.00–325.00)
BMI			
< 18.5 kg/m^2			
No.	10	1	9
Mean (95% CI)	319.9 (95.99–543.91)	330.0 (NA–NA)	318.8 (63.60–574.07)
Median (Q1–Q3)	232.5 (94.50–421.88)	330.0 (330.00–330.00)	150.0 (86.00–452.50)
18.5 to < 25.0 kg/m^2 (ref)			
No.	45	14	31
Mean (95% CI)	214.4 (125.49–303.35)	118.4 (54.47–182.31)	257.8 (132.34–383.22)
Median (Q1–Q3)	120.0 (7.50–270.00)	82.5 (20.62–206.25)	180.0 (18.75–315.00)
25.0 to < 30.0 kg/m^2			
No.	25	6	19
Mean (95% CI)	197.9 (125.47–270.33)	117.5 (36.36–198.64)	223.3 (131.14–315.44)
Median (Q1–Q3)	180.0 (90.00–225.00)	120.0 (78.75–172.50)	195.0 (90.00–262.50)
≥ 30.0 kg/m^2			
No.	12	4	8
Mean (95% CI)	155.4 (75.17–235.66)	237.5 (–36.15–511.15)	114.4 (46.37–182.38)
Median (Q1–Q3)	150.0 (45.00–206.25)	225.0 (146.25–316.25)	90.0 (45.00–183.75)
Smoking status			
Current			
No.	8	5	3
Mean (95% CI)	108.1 (23.46–192.79)	105.0 (–18.54–228.54)	113.3 (–201.22–427.88)
Median (Q1–Q3)	90.0 (56.25–130.00)	90.0 (75.00–90.00)	90.0 (45.00–170.00)
Former			
No.	26	3	23
Mean (95% CI)	133.0 (74.55–191.37)	175.0 (–67.44–417.44)	127.5 (62.43–192.53)
Median (Q1–Q3)	80.5 (33.75–191.25)	180.0 (127.50–225.00)	61.0 (18.75–187.50)

(Continued to the next page)

https://doi.org/10.5217/ir.2024.00007 • Intest Res 2025;23(1):65-75

Supplementary Table 1. Continued

Induction baseline characteristic	Filgotinib 200 mg		
	Total (n = 92)	CS-free remission[a] (n = 25)	No CS-free remission[b] (n = 67)
Never (ref)			
No.	58	17	41
Mean (95% CI)	264.5 (188.09–340.83)	152.5 (83.22–221.78)	310.9 (208.40–413.37)
Median (Q1–Q3)	195.0 (63.75–322.50)	150.0 (45.00–225.00)	215.0 (90.00–435.00)
History of pancolitis			
Yes			
No.	47	13	34
Mean (95% CI)	184.4 (121.65–247.16)	120.6 (53.55–187.61)	208.8 (125.52–292.10)
Median (Q1–Q3)	90.0 (45.00–232.50)	90.0 (45.00–180.00)	105.0 (48.75–247.50)
No (ref)			
No.	42	11	31
Mean (95% CI)	250.9 (160.37–341.48)	147.3 (77.05–217.50)	287.7 (168.04–407.36)
Median (Q1–Q3)	180.0 (78.75–296.25)	150.0 (67.50–247.50)	195.0 (105.00–372.50)
Unknown			
No.	3	1	2
Mean (95% CI)	151.7 (–500.90–804.24)	455.0 (NA–NA)	0.0 (0.00–0.00)
Median (Q1–Q3)	0.0 (0.00–227.50)	455.0 (455.00–455.00)	0.0 (0.00–0.00)
Duration of UC, years			
< 3 (ref)			
No.	28	8	20
Mean (95% CI)	180.8 (108.97–252.53)	137.8 (35.72–239.91)	197.9 (101.88–293.97)
Median (Q1–Q3)	120.0 (43.12–241.25)	97.5 (56.25–191.25)	150.0 (35.62–241.25)
3 to < 7			
No.	27	6	21
Mean (95% CI)	238.7 (128.86–348.62)	150.0 (20.96–279.04)	264.1 (124.92–403.27)
Median (Q1–Q3)	180.0 (60.00–287.50)	180.0 (45.00–247.50)	180.0 (60.00–315.00)
≥ 7			
No.	37	11	26
Mean (95% CI)	220.4 (126.87–313.88)	149.1 (58.94–239.25)	250.5 (120.98–380.08)
Median (Q1–Q3)	150.0 (60.00–240.00)	90.0 (75.00–217.50)	172.5 (48.75–266.25)
Fecal calprotectin level[c]			
≤ 500.0 μg/g (ref)			
No.	19	6	13
Mean (95% CI)	280.5 (141.45–419.60)	198.3 (47.98–348.69)	318.5 (116.77–520.15)
Median (Q1–Q3)	180.0 (90.00–362.50)	150.0 (105.00–240.00)	195.0 (90.00–470.00)
> 500.0 to 1,320.5 μg/g			
No.	16	2	14
Mean (95% CI)	195.5 (–10.42–401.52)	165.0 (–1,169.15–1,499.15)	199.9 (–38.53–438.35)
Median (Q1–Q3)	52.5 (0.00–157.50)	165.0 (112.50–217.50)	41.2 (0.00–112.50)

(Continued to the next page)

Supplementary Table 1. Continued

Induction baseline characteristic	Filgotinib 200 mg		
	Total (n = 92)	CS-free remission[a] (n = 25)	No CS-free remission[b] (n = 67)
> 1,320.5 to 2,658.0 µg/g			
No.	23	4	19
Mean (95% CI)	167.8 (114.83–220.82)	93.8 (–26.98–214.48)	183.4 (122.60–244.24)
Median (Q1–Q3)	180.0 (82.50–225.00)	97.5 (56.25–135.00)	195.0 (90.00–232.50)
> 2,658.0 µg/g			
No.	31	12	21
Mean (95% CI)	222.3 (144.02–300.49)	145.0 (65.64–224.36)	266.4 (151.53–381.28)
Median (Q1–Q3)	180.0 (60.00–315.00)	135.0 (33.75–236.25)	180.0 (61.00–440.00)
Missing			
No.	1	1	-
Mean (95% CI)	7.5 (NA–NA)	7.5 (NA–NA)	
Median (Q1–Q3)	7.5 (7.50–7.50)	7.5 (7.50–7.50)	
CRP level[c]			
≤ 1.690 mg/L (ref)			
No.	29	4	25
Mean (95% CI)	283.4 (151.74–415.07)	245.0 (–39.42–529.42)	289.6 (137.60–441.50)
Median (Q1–Q3)	195.0 (60.00–435.00)	225.0 (108.75–361.25)	195.0 (30.00–435.00)
> 1.690 to 4.415 mg/L			
No.	20	9	11
Mean (95% CI)	221.1 (107.29–334.96)	147.5 (59.31–235.69)	281.4 (76.48–486.24)
Median (Q1–Q3)	150.0 (60.00–281.25)	150.0 (60.00–225.00)	150.0 (75.00–367.50)
> 4.415 to 11.550 mg/L			
No.	25	6	19
Mean (95% CI)	149.1 (87.29–210.87)	105.0 (5.44–204.56)	163.0 (84.50–241.50)
Median (Q1–Q3)	120.0 (37.50–240.00)	82.5 (52.50–135.00)	180.0 (22.50–245.00)
> 11.550 mg/L			
No.	18	6	12
Mean (95% CI)	182.9 (95.01–270.82)	117.5 (2.07–232.93)	215.6 (89.68–341.57)
Median (Q1–Q3)	157.5 (48.75–233.75)	127.5 (18.75–180.00)	165.0 (56.25–290.00)
MCS			
≤ 8			
No.	26	9	17
Mean (95% CI)	202.8 (81.19–324.37)	131.4 (12.13–250.65)	240.6 (58.66–422.48)
Median (Q1–Q3)	142.5 (31.88–258.75)	75.0 (7.50–225.00)	215.0 (37.50–275.00)
≥ 9 (ref)			
No.	66	16	50
Mean (95% CI)	218.0 (160.62–275.39)	153.8 (97.80–209.70)	238.6 (164.94–312.20)
Median (Q1–Q3)	150.0 (60.00–270.00)	150.0 (75.00–225.00)	150.0 (60.00–322.50)
MES			
2			
No.	33	16	17
Mean (95% CI)	246.3 (141.53–351.12)	165.8 (100.06–231.50)	322.1 (124.45–519.82)
Median (Q1–Q3)	195.0 (60.00–275.00)	165.0 (71.25–236.25)	225.0 (60.00–305.00)

(Continued to the next page)

https://doi.org/10.5217/ir.2024.00007 • Intest Res 2025;23(1):65-75

Supplementary Table 1. Continued

Induction baseline characteristic	Filgotinib 200 mg		
	Total (n = 92)	CS-free remission[a] (n = 25)	No CS-free remission[b] (n = 67)
3 (ref)			
No.	59	9	50
Mean (95% CI)	195.5 (136.57–254.35)	110.0 (17.94–202.06)	210.8 (143.27–278.41)
Median (Q1–Q3)	120.0 (41.25–245.00)	75.0 (0.00–150.00)	127.5 (48.75–247.50)
Rectal Bleeding Subscore < 2			
Yes			
No.	33	8	25
Mean (95% CI)	274.4 (154.39–394.47)	129.1 (4.19–253.94)	321.0 (168.17–473.73)
Median (Q1–Q3)	180.0 (45.00–325.00)	82.5 (46.88–146.25)	195.0 (45.00–452.50)
No (ref)			
No.	59	17	42
Mean (95% CI)	179.7 (131.90–227.58)	153.5 (95.85–211.21)	190.3 (126.21–254.48)
Median (Q1–Q3)	150.0 (60.00–255.00)	150.0 (75.00–270.00)	120.0 (60.00–236.25)
Stool Frequency Subscore ≤ 2			
Yes			
No.	40	12	28
Mean (95% CI)	190.7 (103.75–277.74)	101.9 (36.24–167.51)	228.8 (107.75–349.91)
Median (Q1–Q3)	105.0 (24.38–236.25)	75.0 (5.62–168.75)	150.0 (35.62–298.75)
No (ref)			
No.	52	13	39
Mean (95% CI)	231.4 (165.11–297.62)	186.2 (108.31–263.99)	246.4 (160.76–332.11)
Median (Q1–Q3)	180.0 (71.25–282.50)	180.0 (90.00–270.00)	180.0 (60.00–290.00)
Biologic-naive			
Yes			
No.	44	18	26
Mean (95% CI)	176.0 (117.78–234.31)	159.9 (93.27–226.45)	187.2 (96.34–278.16)
Median (Q1–Q3)	135.0 (52.50–270.00)	135.0 (75.00–270.00)	135.0 (37.50–225.00)
No (ref)			
No.	48	7	41
Mean (95% CI)	248.2 (162.33–334.12)	109.3 (30.93–187.64)	271.9 (173.24–370.65)
Median (Q1–Q3)	180.0 (56.25–287.50)	75.0 (52.50–180.00)	195.0 (60.00–435.00)
Prior use of TNF-α antagonist, induction study B participants			
Yes			
No.	45	6	39
Mean (95% CI)	261.1 (170.65–351.56)	115.0 (19.16–210.84)	283.6 (181.09–386.08)
Median (Q1–Q3)	180.0 (60.00–325.00)	120.0 (48.75–180.00)	195.0 (73.00–437.50)
No (ref)			
No.	4	1	3
Mean (95% CI)	86.2 (–31.29–203.79)	75.0 (NA–NA)	90.0 (–133.57–313.57)
Median (Q1–Q3)	82.5 (56.25–112.50)	75.0 (75.00–75.00)	90.0 (45.00–135.00)

(Continued to the next page)

Supplementary Table 1. Continued

Induction baseline characteristic	Filgotinib 200 mg		
	Total (n = 92)	CS-free remission[a] (n = 25)	No CS-free remission[b] (n = 67)
Prior failure of TNF-α antagonist, induction study B participants			
Yes			
No.	43	6	37
Mean (95% CI)	268.0 (174.03–362.00)	115.0 (19.16–210.84)	292.8 (185.77–399.89)
Median (Q1–Q3)	180.0 (60.00–380.00)	120.0 (48.75–180.00)	195.0 (86.00–440.00)
No (ref)			
No.	6	1	5
Mean (95% CI)	95.0 (–1.87–191.87)	75.0 (NA–NA)	99.0 (–28.41–226.41)
Median (Q1–Q3)	82.5 (18.75–157.50)	75.0 (75.00–75.00)	90.0 (0.00–180.00)
Prior use of vedolizumab, induction study B participants			
Yes			
No.	29	3	26
Mean (95% CI)	255.5 (130.44–380.51)	160.0 (–31.21–351.21)	266.5 (126.96–406.02)
Median (Q1–Q3)	180.0 (75.00–240.00)	180.0 (127.50–202.50)	157.5 (56.25–303.75)
No (ref)			
No.	20	4	16
Mean (95% CI)	234.3 (122.39–346.21)	71.2 (–51.04–193.54)	275.1 (141.98–408.15)
Median (Q1–Q3)	180.0 (56.25–315.00)	52.5 (33.75–90.00)	205.0 (79.50–436.25)
Prior failure of vedolizumab, induction study B participants			
Yes			
No.	24	2	22
Mean (95% CI)	288.1 (139.50–436.64)	202.5 (–83.39–488.39)	295.9 (133.08–458.62)
Median (Q1–Q3)	187.5 (78.75–361.25)	202.5 (191.25–213.75)	187.5 (56.25–433.75)
No (ref)			
No.	25	5	20
Mean (95% CI)	207.2 (115.33–299.15)	72.0 (–10.67–154.67)	241.1 (130.61–351.49)
Median (Q1–Q3)	150.0 (60.00–250.00)	60.0 (45.00–75.00)	187.5 (79.50–315.00)
Prior use of TNF-α antagonist and vedolizumab, induction study B participants			
Yes			
No.	26	2	24
Mean (95% CI)	278.6 (141.36–415.85)	202.5 (–83.39–488.39)	284.9 (135.71–434.18)
Median (Q1–Q3)	187.5 (90.00–303.75)	202.5 (191.25–213.75)	187.5 (78.75–361.25)
No (ref)			
No.	23	5	18
Mean (95% CI)	210.9 (110.98–310.84)	72.0 (–10.67–154.67)	249.5 (126.87–372.13)
Median (Q1–Q3)	150 (52.50–262.50)	60.0 (45.00–75.00)	187.5 (66.50–395.00)
Concomitant aminosalicylates			
Yes			
No.	73	22	51
Mean (95% CI)	186.2 (141.87–230.58)	151.6 (95.25–207.93)	201.2 (141.84–260.50)
Median (Q1–Q3)	150.0 (60.00–270.00)	120.0 (63.75–258.75)	150.0 (52.50–262.50)

(Continued to the next page)

https://doi.org/10.5217/ir.2024.00007 • Intest Res 2025;23(1):65-75

Supplementary Table 1. Continued

Induction baseline characteristic	Filgotinib 200 mg		
	Total (n = 92)	CS-free remission[a] (n = 25)	No CS-free remission[b] (n = 67)
No (ref)			
No.	19	3	16
Mean (95% CI)	319.3 (124.39–514.16)	102.5 (–115.04–320.04)	359.9 (131.34–588.50)
Median (Q1–Q3)	180.0 (67.50–372.50)	120.0 (63.75–150.00)	197.5 (78.75–478.75)

[a]Patients who achieved clinical remission at week 58 without using CS to treat UC over a continuous period of at least 6 months.
[b]Patients who did not achieve clinical remission at week 58 without using CS to treat UC over a continuous period of at least 6 months.
[c]Ranges represent division of the data set by the three quartiles.
CS, corticosteroid; CI, confidence interval; Q, quartile; ref, reference; BMI, body mass index; NA, not applicable; UC, ulcerative colitis; CRP, C-reactive protein; MCS, Mayo Clinic Score; MES, Mayo Clinic Endoscopic Subscore; TNF, tumor necrosis factor.